ONCOLYTICS BIOTECH INC (ONCY) Fundamental Analysis & Valuation

NASDAQ:ONCY • CA6823108759

Current stock price

0.9004 USD
-0.07 (-7.05%)
At close:
0.9189 USD
+0.02 (+2.05%)
After Hours:

This ONCY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ONCY Profitability Analysis

1.1 Basic Checks

  • In the past year ONCY has reported negative net income.
  • In the past year ONCY has reported a negative cash flow from operations.
  • In the past 5 years ONCY always reported negative net income.
  • ONCY had a negative operating cash flow in each of the past 5 years.
ONCY Yearly Net Income VS EBIT VS OCF VS FCFONCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of ONCY (-152.26%) is worse than 84.85% of its industry peers.
  • With a Return On Equity value of -499.46%, ONCY is not doing good in the industry: 78.45% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONCY Yearly ROA, ROE, ROICONCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

  • ONCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCY Yearly Profit, Operating, Gross MarginsONCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

2

2. ONCY Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ONCY has more shares outstanding
  • The number of shares outstanding for ONCY has been increased compared to 5 years ago.
  • The debt/assets ratio for ONCY is higher compared to a year ago.
ONCY Yearly Shares OutstandingONCY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONCY Yearly Total Debt VS Total AssetsONCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • ONCY has an Altman-Z score of -32.16. This is a bad value and indicates that ONCY is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -32.16, ONCY is doing worse than 89.90% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that ONCY is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.10, ONCY is not doing good in the industry: 63.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -32.16
ROIC/WACCN/A
WACCN/A
ONCY Yearly LT Debt VS Equity VS FCFONCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 2.88 indicates that ONCY has no problem at all paying its short term obligations.
  • ONCY has a Current ratio of 2.88. This is in the lower half of the industry: ONCY underperforms 64.08% of its industry peers.
  • A Quick Ratio of 2.88 indicates that ONCY has no problem at all paying its short term obligations.
  • ONCY's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ONCY is outperformed by 62.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
ONCY Yearly Current Assets VS Current LiabilitesONCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

1

3. ONCY Growth Analysis

3.1 Past

  • ONCY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.36%.
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ONCY will show a very strong growth in Earnings Per Share. The EPS will grow by 37.86% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCY Yearly Revenue VS EstimatesONCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONCY Yearly EPS VS EstimatesONCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

0

4. ONCY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ONCY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCY Price Earnings VS Forward Price EarningsONCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCY Per share dataONCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y10.11%

0

5. ONCY Dividend Analysis

5.1 Amount

  • No dividends for ONCY!.
Industry RankSector Rank
Dividend Yield 0%

ONCY Fundamentals: All Metrics, Ratios and Statistics

ONCOLYTICS BIOTECH INC

NASDAQ:ONCY (4/28/2026, 4:53:29 PM)

After market: 0.9189 +0.02 (+2.05%)

0.9004

-0.07 (-7.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-01
Inst Owners2.24%
Inst Owner Change0%
Ins Owners3.22%
Ins Owner Change17.1%
Market Cap104.56M
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Analysts77.5
Price TargetN/A
Short Float %5.71%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)20.79%
Max EPS beat(2)35.03%
EPS beat(4)3
Avg EPS beat(4)14.8%
Min EPS beat(4)-15.35%
Max EPS beat(4)35.03%
EPS beat(8)6
Avg EPS beat(8)14.12%
EPS beat(12)8
Avg EPS beat(12)8.97%
EPS beat(16)11
Avg EPS beat(16)10.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.36
P/tB 23.36
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -32.16
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y0.67%
FCF growth 1Y6.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.92%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLYTICS BIOTECH INC / ONCY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ONCOLYTICS BIOTECH INC (ONCY) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ONCY.


What is the valuation status of ONCOLYTICS BIOTECH INC (ONCY) stock?

ChartMill assigns a valuation rating of 0 / 10 to ONCOLYTICS BIOTECH INC (ONCY). This can be considered as Overvalued.


Can you provide the profitability details for ONCOLYTICS BIOTECH INC?

ONCOLYTICS BIOTECH INC (ONCY) has a profitability rating of 0 / 10.